Actively Recruiting
Randomized Study Comparing BMN 333 and Vosoritide for Growth in Children with Achondroplasia
Led by BioMarin Pharmaceutical · Updated on 2026-10-22
160
Participants Needed
28
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating BMN 333 in children with achondroplasia who have not previously received growth-promoting treatments. This multinational, multicenter study is a randomized, active-controlled Phase 23 trial comparing BMN 333 with vosoritide to assess their effects on growth. The main goal is to determine how BMN 333 influences growth velocity compared with vosoritide in this pediatric population. The study is divided into two parts Phase 2 focuses on selecting the optimal dose of BMN 333 and deciding whether to continue to Phase 3, while Phase 3 compares the selected BMN 333 dose with vosoritide. Participants receive BMN 333 as a weekly subcutaneous injection or vosoritide as a daily subcutaneous injection. Treatment lasts for 52 weeks, followed by a safety follow-up, with the overall study duration up to 61 weeks from screening. During the trial, participants undergo assessments of annualized growth velocity and changes in height and body proportions. Researchers monitor safety through adverse event tracking and blood concentration levels of the study drugs. The study includes genetic testing confirmation of achondroplasia, evaluation of growth parameters, and regular monitoring visits, with the study ending after a safety follow-up visit.
CONDITIONS
Brief Title
Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
Research Team
T
Trial Specialist
S
Study Manager
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here